Chiotis, Konstantinos
Stenkrona, Per
Almkvist, Ove
Stepanov, Vladimir
Ferreira, Daniel
Arakawa, Ryosuke
Takano, Akihiro
Westman, Eric
Varrone, Andrea
Okamura, Nobuyuki
Shimada, Hitoshi
Higuchi, Makoto
Halldin, Christer
Nordberg, Agneta
Funding for this research was provided by:
Vetenskapsrådet (05817)
Stiftelsen för Strategisk Forskning
Regional Agreement on Medical Training and Clinical Research (ALF) for Stockholm County Council
Stiftelsen för Gamla Tjänarinnor
Stiftelsen Sigurd and Elsa Goljes Minne
Axel Linders Stiftelse
Gun och Bertil Stohnes Stiftelse
KI Funds
Hjärnfonden
Alzheimerfonden
Demensförbundet
KTH-SLL grants
EU FW7 large-scale integrating project INMiND
Article History
Received: 21 January 2018
Accepted: 6 April 2018
First Online: 12 May 2018
Compliance with ethical standards
:
: H.S. and M.H. hold a patent on the PET tracer PBB3, which was used in the study reported here (JP 5422782/EP 12 884 742.3). N.O. receives royalties from GE Healthcare Corp. for the PET tracer THK5351, which was used in the study reported here.All other authors declare no conflicts on interest.
: The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, and by the Medical Products Agency in Sweden (Läkemedelsverket; EudraCT: 2015–005506-11). The use of all tracers was approved by the Radiation Safety Committee at the Karolinska University Hospital, Stockholm, Sweden, and all procedures were in accordance with the ethical standards of the institutional and national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards, as well as with those of the International Conference on Harmonisation/Good Clinical Practice guidelines.
: All participants and their caregivers provided written informed consent prior to the investigation